Jennifer K. Moses's Insider Trades & SAST Disclosures
Jennifer K. Moses's most recent trade in Viridian Therapeutics Inc was a trade of 21,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 26, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jennifer K. Moses.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc | Jennifer K. Moses | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 21,000 | 21,000 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Jennifer K. Moses | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 44,600 | 44,600 | - | - | Stock Options (Right to buy) | |
| G1 Therapeutics Inc | Jennifer K. Moses | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 22,300 | 60,188 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Jennifer K. Moses | CFO | Sale of securities on an exchange or to another person at price $ 5.58 per share. | 03 Jan 2023 | 1,639 | 58,549 (0%) | 0% | 5.6 | 9,138 | Common Stock |
| G1 Therapeutics Inc | Jennifer K. Moses | CFO | Sale of securities on an exchange or to another person at price $ 5.41 per share. | 03 Jan 2023 | 729 | 57,820 (0%) | 0% | 5.4 | 3,942 | Common Stock |
| Viridian Therapeutics Inc | Jennifer K. Moses | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Jennifer K. Moses | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 2,000 | 58,000 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Jennifer K. Moses | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.17 per share. | 01 Feb 2022 | 2,000 | 37,888 (0%) | 0% | 4.2 | 8,340 | Common Stock |
| G1 Therapeutics Inc | Jennifer K. Moses | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 333 | 0 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Jennifer K. Moses | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 01 Feb 2022 | 333 | 35,888 (0%) | 0% | 3.7 | 1,239 | Common Stock |
| G1 Therapeutics Inc | Jennifer K. Moses | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 53,000 | 53,000 | - | - | Stock Options (Right to buy) | |
| G1 Therapeutics Inc | Jennifer K. Moses | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 12,000 | 37,000 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Jennifer K. Moses | CFO | Sale of securities on an exchange or to another person at price $ 10.61 per share. | 03 Jan 2022 | 1,445 | 35,555 (0%) | 0% | 10.6 | 15,334 | Common Stock |
| Viridian Therapeutics Inc | Jennifer K. Moses | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Jennifer K. Moses | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 03 Mar 2021 | 3,000 | 25,000 (0%) | 0% | 3.7 | 11,160 | Common Stock |
| G1 Therapeutics Inc | Jennifer K. Moses | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2021 | 3,000 | 333 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Jennifer K. Moses | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 58,000 | 58,000 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Jennifer K. Moses | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 11,000 | 22,000 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges